Compare Quest Diagnostics Inc (DGX) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global E Online Ltd — how do they compare? Quest Diagnostics Inc trades at $230.78 (market cap $25.48B), while Global E Online Ltd trades at $40.13 (market cap $6.75B). The key difference: Quest Diagnostics Inc is far larger — about 3.8× Global E Online Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Global E Online Ltd for 21 Days on average.
| DGX | GLBE | |
|---|---|---|
Market Cap | $25.48B | $6.75B |
Volume | 941,866 | 1,468,708 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $42.36 |
52-Week Low | $173.49 | $27.54 |
Typical Hold Time | 56 Days | 21 Days |
Enterprise Value | $31.23B | $6.24B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
GLBE trades at $40.22, up 3.23% with strong analyst support (14 buys, 1 hold). The stock shows bullish technical momentum above key support at $40, while fundamentals reveal robust revenue growth from $962M in 2025 to $1.1B projected for 2026. Recent Q2 earnings beat expectations with 44% GMV growth, though insider selling and elevated P/E of 45.65 warrant caution.
Outlook remains positive given raised 2026 guidance and 28% upside to consensus target of $48.86. Key risks include valuation sensitivity to growth execution and persistent insider selling. The appointment of a new Chief Revenue Officer signals strategic focus on scaling, but investors should monitor quarterly execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
